Paul Benton, International Director at the ABHI shares our story as to how we entered the US marketplace
Appointed sales and distribution partners, dedicated warehouse facilities and new US customers are just some of the outcomes from the UK MedTech missions to Texas. Read more
Encouraged by the growing national recognition of the value of urine in diagnostic medicine, health leaders are being approached to join a new Forte Medical Advisory Board. Three leading exponents of accurate basic medicine have so far been appointed: Mike Farrar (pic) who will Chair the panel, Dr Katherine Brown and Rachel Cashman
Mike Farrar is a management consultant with 15 years of CEO experience in the NHS, having stepped down as the Chief Executive of the NHS Confederation in September 2013. Mike has been a member of the PwC Health Industries Oversight Board and has worked on major projects across the country. Mike has also built alongside this a successful business practice working with clients such as Celesio, ROGP, ABPI, NHS Quest, NHS Leadership Academy, Health Foundation, Vanguard Health Solutions, Pfizer, CIPFA and others, as well as starting up a number of small companies aimed at promoting health innovations, and links between health and sport.
He has been Chief Executive of North West England SHA, West Yorkshire, and South Yorkshire Strategic Health Authorities and Tees Valley Health Authority and Head of Primary Care at the Department of Health. Mike remains a prominent thought leader and consultant to the NHS throughout the UK
Dr Katherine Brown is an academic based in the UK and the US with over 100 peer-reviewed publications. She is affiliated with Cambridge and Imperial Universities and the University of Texas. With over 25 years in medical applications, she has extensive expertise in biochemistry, biophysics, infectious disease and bio/nanotechnology.
Rachel Cashman is Managing Director, The Soircas Consultancy and former Head of Clinical and Scientific Policy and Strategy, NHS England
During her 20+ years in the healthcare and life sciences sectors, Rachel has delivered large-scale change and innovation through inter-sectoral collaboration and the development of networks. At NHS England, she led the establishment of Academic Health Science Networks (AHSNs) and the process to create the first nationally commissioned network of Genomic Medicine Centres, utilising the latest scientific techniques in understanding human DNA in order to better predict, precisely diagnose and personalise treatment of cancers and rare disease.
She has worked with NHS Trusts and CCGs and their local health and care system partners to develop appropriate governance and infrastructure in response to the NHS Five Year Forward View and the emergence of the Sustainability and Transformation Partnerships. As a Board member at University Hospitals Birmingham NHS Foundation Trust and Heart of England NHS Trust, Rachel designed the strategic business case and engagement process for the proposed merger. Rachel has played an integral role in helping the NHS utilise rapid assessment protocols to evaluate potential partnership opportunities such as hospital chains, franchise models, mergers, accountable care organisations and multi-specialty community provider organisations.
2017 has been described as the ‘year of Femtech’, with start-ups focusing on innovation in women’s health starting to enjoy an increased profile. In this, the latest episode of MHP’s ‘On Message’ podcasts, Giovanna Forte joins host Darika Ahrens and business women Lisa Kennelly, Andrea Zitna, Paul Armstrong, Madeleine Harris Smith and Christian Pickel to discuss the opportunities and challenges around communicating Femtech to investors, the media and consumers.
The appointment of Andrew Turner as Business Development lead has brought new life to the introduction of Peezy Midstream technology to a number of leading NHS Trusts open to “getting it right first time” and reducing costs by making patients better, faster.
Eight Trusts have formed a collaboration of Microbiology, Nursing Directorates, Antimicrobial Resistance leads and others to oversee evaluations. This is the first time we have had access to cross-departmental evaluation, breaking down the decision-making silos that still dominate change within the NHS. Andrew has spent 25 years working across microbiology, medical devices and system change within the NHS and private health sectors in the UK and overseas.
As a regular participant of the ABHI Trade Missions to Texas, we are delighted to be part of this exciting development….
The Association of British Healthcare Industries (ABHI) and the Dell Medical School at The University of Texas at Austin are delighted to announce the establishment of the “ABHI Innovation Hub”.
The creation of the Hub, a first for ABHI, will offer UK companies the opportunity to locate themselves at a world-class facility and develop their US business within an ecosystem of clinicians, investors and mentors. It offers companies a compelling office location, providing them the infrastructure to focus on accelerating market access in Texas and beyond.
The Hub will be located within Dell Med’s Health CoLab, a new initiative that provides space and creates connections for start-up companies that share the school’s mission to create healthier communities, starting in Austin and the surrounding area. The Health CoLab directly supports the school, seeking out innovation that promotes health, enhances medical services, increases care resources and access for people in this community in ways that can be scaled to other communities.
“The ABHI Innovation Hub at Dell Medical School will offer UK companies a unique opportunity to collaborate in a truly world class facility,” said Phil Kennedy, Chairman of the ABHI. “The Hub will support promising medical technology innovation whilst looking to develop value based healthcare for the benefit of patients in Texas, throughout the US and at home in the UK.”
The Dell Medical School has a strong focus on supporting health entrepreneurs and businesses. In addition to the CoLab, companies that base themselves in the Innovation Hub will be able to participate in the ‘Texas Health Catalyst,’ a programme designed by the Dell Medical School to foster health research and advance innovation.
“We are very excited to be working with ABHI to strengthen ties between the UK and Austin across a variety of health and technology areas,” said Ruben Rathnasingham, Assistant Dean for Health Product Innovation at Dell Medical School. “We look forward to working with the ABHI, its members and the UK going forward.”
The partnership also extends support to Texas-based companies that are looking to understand and enter the UK healthcare market. Through ABHI’s International Membership scheme, companies looking to introduce innovative medical technology (MedTech) to the UK will be offered insight and market-access knowledge, as well as assistance from a number of partner organisations, including the UK’s Department of International Trade.
“Through this collaboration, companies will be closer to a range of innovation initiatives that we have created and are continuing to create at Dell Med,” said Mellie Price, the school’s Executive Director of Commercialization. “They will find themselves in a rich, creative environment.”